Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.

Scientific reports - 21 Feb 2017

Peng Cheng-Yuan, Lai Hsueh-Chou, Su Wen-Pang, Lin Chia-Hsin, Chuang Po-Heng, Chen Sheng-Hung, Chen Ching-Hsiang

Abstract excerpt

Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334 HBeAg-negative) with a median treatment duration of 49.2 months. Median HBsAg levels declined significantly in both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Guanine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to Predictive Value of Tests

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 28220833
DOI: 10.1038/srep42879
PMCID: PMC5318891

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.PMID 28220833Read ↗

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.Semantic proximity Read ↗

Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.Semantic proximity Read ↗

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.Semantic proximity Read ↗

Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.Semantic proximity Read ↗

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.Semantic proximity Read ↗

Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.Semantic proximity Read ↗

Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.Semantic proximity Read ↗

Predictive Factors for HBsAg Loss in Chronic HBeAg-Negative Hepatitis B Virus Infection: Insights From a 5-Year French Cohort.Semantic proximity Read ↗

Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection.Semantic proximity Read ↗

Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Semantic proximity Read ↗

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.Semantic proximity Read ↗

Distinct seromarkers predict different milestones of chronic hepatitis B progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.